The Multi-Objective Computational Design and Prioritization of Novel TSPO PET Radioligands for Improved Inflammation Imaging after Traumatic Brain Injury

Clinicians employ TSPO PET imaging to quantify the extent of TBI-associated neuroinflammation through radioligands that bind to the central pocket of the human translocator protein. However, many radioligands underperform due to pocket dissociation and low blood-brain barrier permeability. I hypothesize that a targeted cheminformatic pipeline can accelerate the pre-synthetic design of novel TSPO ligands with improved physicochemistry. Eight second-generation ligands were benchmarked using preclinical physicochemical and PET metrics. Emapunil was selected as the modifiable scaffold. Haloalkylation was curated across two functional groups, establishing a 1922-analog dataset. Following prioritization based on molecular descriptors and docking energy, 15 lead candidates (assigned IDs of A#) proceeded to PBPK modeling. Leads were z-scored, and the top three candidates advanced to plasma-input Logan analysis. Consensus ADMET prioritized leads for short-timescale molecular dynamics. The top four analogs were evaluated through a five-replicate 10-ns MD panel along with the reference, and retrosynthetic routes were devised through ASKCOS. A7 showed a significantly improved static and dynamic profile over emapunil. A7 displayed a 5.4-fold increase in partition coefficient and fourfold increase in brain-plasma concentration ratio in the PBPK simulations versus the reference. Logan VT slope estimates were stable for A3, A6, and A7. MD showed A7 retained 28.25±5.94 mean fixed-pocket contacts and ≥10 contacts in 97.96±2.04% of frames. A7’s contact advantage over AC-5216 was statistically significant after Holm correction (p=0.0317). ASKCOS predicted 200 complete synthetic routes for A3, A8, A15, and emapunil with buyable terminals, while A7 displayed an unresolved N-difluoromethylation terminal. Pareto analysis identified A7 as the only nondominated analog. A7 emerged as the strongest radioligand candidate and demonstrates the effectiveness of a cohesive cheminformatic system in PET radioligand development.

Authors

Publication Details

Journal
ChemRxiv
Published
2026-11-16
DOI
https://doi.org/10.26434/chemrxiv.15003660/v2
Primary Topic
Computational Drug Discovery Methods
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

The Multi-Objective Computational Design and Prioritization of Novel TSPO PET Radioligands for Improved Inflammation Imaging after Traumatic Brain Injury

Dhruv Subramanian
ChemRxiv
Computational Drug Discovery Methods
preprint

The Multi-Objective Computational Design and Prioritization of Novel TSPO PET Radioligands for Improved Inflammation Imaging after Traumatic Brain Injury

Dhruv Subramanian
preprint en

Abstract

Clinicians employ TSPO PET imaging to quantify the extent of TBI-associated neuroinflammation through radioligands that bind to the central pocket of the human translocator protein. However, many radioligands underperform due to pocket dissociation and low blood-brain barrier permeability. I hypothesize that a targeted cheminformatic pipeline can accelerate the pre-synthetic design of novel TSPO ligands with improved physicochemistry. Eight second-generation ligands were benchmarked using preclinical physicochemical and PET metrics. Emapunil was selected as the modifiable scaffold. Haloalkylation was curated across two functional groups, establishing a 1922-analog dataset. Following prioritization based on molecular descriptors and docking energy, 15 lead candidates (assigned IDs of A#) proceeded to PBPK modeling. Leads were z-scored, and the top three candidates advanced to plasma-input Logan analysis. Consensus ADMET prioritized leads for short-timescale molecular dynamics. The top four analogs were evaluated through a five-replicate 10-ns MD panel along with the reference, and retrosynthetic routes were devised through ASKCOS. A7 showed a significantly improved static and dynamic profile over emapunil. A7 displayed a 5.4-fold increase in partition coefficient and fourfold increase in brain-plasma concentration ratio in the PBPK simulations versus the reference. Logan VT slope estimates were stable for A3, A6, and A7. MD showed A7 retained 28.25±5.94 mean fixed-pocket contacts and ≥10 contacts in 97.96±2.04% of frames. A7’s contact advantage over AC-5216 was statistically significant after Holm correction (p=0.0317). ASKCOS predicted 200 complete synthetic routes for A3, A8, A15, and emapunil with buyable terminals, while A7 displayed an unresolved N-difluoromethylation terminal. Pareto analysis identified A7 as the only nondominated analog. A7 emerged as the strongest radioligand candidate and demonstrates the effectiveness of a cohesive cheminformatic system in PET radioligand development.

ChemRxiv
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon